mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究

doi:10.3969/j.issn.1004-616x.2020.06.007

Abstract

Abstract: OBJECTIVE: To investigate the effect of mTOR inhibitor,AZD2014,on proliferation of HCC cells. METHODS: The CCK-8 method was used to detect proliferation of HCC cells after their treatment with different concentrations of AZD2014 (10,100,500,1 000 nmol/L). Expression levels of UHRF1 mRNA and protein were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western Blot,respectively. RESULTS: The CCK-8 results show that different concentrations of AZD2014 (10,100,500,1 000 nmol/L) significantly inhibited proliferation of hepatoma cells,and the degree of inhibition was positively dose-dependent. In addition,the RT-PCR and Western Blot data show that AZD2014 at concentrations of 500 nmol/L and 1 000 nmol/L reduced the expression of UHRF1 mRNA and protein in HCC cells. CONCLUSION: AZD2014 inhibited proliferation of HCC cells by repressing expression of UHRF1.

Key words: mTOR inhibitor, AZD2014, UHRF1, hepatocellular carcinoma, proliferation inhibition

CLC Number:

R735.7

LIN Kaihuang, CAI Gaoyang, LIU Xincheng. Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 448-451.

References

[1] KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):477-491.
[2] RICH N E, PARIKH N D, SINGAL A G. Hepatocellular carcinoma and liver transplantation:changing patterns and practices[J]. Curr Treat Options Gastroenterol, 2017, 15(2):296-304.
[3] LIAO M, ZHONG X, ZHANG J, et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis:a prospective randomized trial[J]. J Surg Oncol, 2017, 115(8):971-979.
[4] GE S H, HUANG D Z. Systemic therapies for hepatocellular carcinoma[J]. Drug Discov Ther, 2015, 9(5):352-362.
[5] CHOI K J, BAIK I H, YE S K, et al. Molecular targeted therapy for hepatocellular carcinoma:present status and future directions[J]. Biol Pharm Bull, 2015, 38(7):986-991.
[6] LIAO H, HUANG Y, GUO B, et al. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma[J]. Am J Cancer Res, 2015, 5(1):125-139.
[7] POWLES T, WHEATER M, DIN O, et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer[J]. Eur Urol, 2016, 69(3):450-456.
[8] WANG C, WANG X, SU Z, et al. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth[J]. Oncol Rep, 2015, 34(4):1708-1716.
[9] FASOLO A, SESSA C. Targeting mTOR pathways in human malignancies[J]. Curr Pharm Des, 2012, 18(19):2766-2777.
[10] AL-BATRAN S E, DUCREUX M, OHTSU A. mTOR as a therapeutic target in patients with gastric cancer[J]. Int J Cancer, 2012, 130(3):491-496.
[11] ZONCU R, EFEYAN A, SABATINI D M. mTOR:from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Biol, 2011, 12(1):21-35.
[12] SARBASSOV D D, GUERTIN D A, ALI S M, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science, 2005, 307(5712):1098-1101.
[13] GUERTIN D A, SABATINI D M. Defining the role of mTOR in cancer[J]. Cancer Cell, 2007, 12(1):9-22.
[14] VILLANUEVA A, CHIANG D Y, NEWELL P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(6):1972-1983.
[15] PENG X G, ZHANG D H, LI Z L, et al. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat[J]. Biochem Biophys Res Commun, 2016, 477(4):556-562.
[16] MILOŠEVIĆ Z, BANKOVIĆ J, DINIĆ J, et al. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma[J]. Cell Oncol (Dordr), 2018, 41(4):409-426.
[17] FUJIMORI A, MATSUDA Y, TAKEMOTO Y, et al. Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation[J]. Mamm Genome, 1998, 9(12):1032-1035.
[18] HASHIMOTO H, HORTON J R, ZHANG X, et al. UHRF1, a modular multi-domain protein, regulates replication-coupled crosstalk between DNA methylation and histone modifications[J]. Epigenetics, 2009, 4(1):8-14.
[19] ZHANG Y, HUANG Z, ZHU Z, et al. Upregulated UHRF1 promotes bladder cancer cell invasion by epigenetic silencing of KiSS1[J]. PLoS One, 2014, 9(10):e104252.
[20] LIU X, OU H, XIANG L, et al. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(6):10510-10522.

Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Xinping, JIA Di, LIN Shaohui, LIU Chen, LI Jingyi, ZHAO Weiming. Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 47-52,66.
[2]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[3]	ZHANG Ju, YE Shulai, ZHANG Changlong, ZHOU Qian. Stimulation of dendritic cell-mediated antitumor tumor effect from HepG2 cell exosomes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(1): 29-34.
[4]	DING Wenping, LU Yuanyuan, TONG Wenxia, ZHOU Aibin, KONG Xiang, CHEN Yihong. Induction of apoptosis in HepG2 hepatocellular carcinoma cells by chloroquine via the P38MAPK pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 430-434.
[5]	ZHAO Ji, LIU Wenbin, CHEN Hongqiang, LIU Jinyi, YANG Huifang, CAO Jia. Expression of the WFDC1 gene in hepatocellular carcinoma tissues and cell lines and their prognostic values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 291-296.
[6]	LIU Dan, JIAO Liangbo, ZHANG Wen, WANG Xinyi, CHEN Tao, HU Wei. Effect of Chinese herbal compound QHF on human Huh7 hepatoma cell proliferation and invasion, and expression of surface markers of cancer stem cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 171-175.
[7]	PENG Wei, QIU Fu. Expression and prognostic influence of TM4SF1 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 427-430,436.
[8]	LIU Dezhong, CHANG Bo, LIN Feixiang, LI Xuedong. β-catenin expression in hepatocellular carcinoma and its effect on prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 300-303.
[9]	CHEN Jiahong, ZHANG Hang, LAI Yi, JIANG Yan, CHEN Tao. Cell proliferation-related mRNA expression and DNA methylation changes induced by trichloroethylene in the liver and kidney of B6C3F1 male mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 211-215.
[10]	WU Lifei1, HAO Jiajie，ZHANG Tongtong，LIANG Jianwei，WANG Zheng，ZHANG Yu，XU Xin，CAI Yan，WANG Mingrong，LI Min. Expression and prognostic value of UHRF1 in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(1): 30-34.
[11]	NIU Yong-dong，CHEN Li-ming，WU Man-peng，CHENG He，XU Han，GAO Fen-fei，SHI Gang-gang. Establishment of a HepG2 cell line with stable PXR silencing by lentivirus-mediated RNA interference [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(3): 209-212.
[12]	CHENG Long-qiang1;ZHANG Yao2;CHEN Chang-jie2;YANG Qing-ling2;WANG Hui1. Expressions of apolipoprotein M, liver receptor homolog-1 and hepatocyte nuclear factor-1α in hepatocellular carcinoma [J]. , 2010, 22(2): 130-133.
[13]	XU Jia1; ZHANG Yin-juan2;LU Gang3;SHAN Bao-en3;. Effects of RNAi Targeted to STAT3 on Apoptosis Induction and on STAT3 Signaling in Human Hepatocellular Carcinoma Cells [J]. , 2009, 21(5): 339-343.
[14]	QIU Li-wei, YAO Deng-fu, JIANG Hua, LI Yue-ming, SAI Wen-li, YUAN Ju-ping, WU Wei, WU Xin-hua. Expression and Changes of Hepatic Hypoxia Inducible Factor-1 during the Development of Hepatocellular Carcinoma [J]. , 2009, 21(1): 10-014.
[15]	LU Hai_xia,FENG Zhen_bo,FENG Xiao_lan. Polymorphisms of CYP3A7 Gene of 210 Persons in Guangxi with Heavy Aflatoxin B1 Contamination [J]. , 2008, 20(4): 292-294.